Ochronotic osteoarthropathy in a mouse model of alkaptonuria, and its inhibition by nitisinone

Annals of the Rheumatic Diseases

Volumn 73, Issue 1, 2014, Pages 284-289

  Preston, Andrew J ^a   Keenan, Craig M ^a   Sutherland, Hazel ^a   Wilson, Peter J ^a   Wlodarski, Brenda ^a   Taylor, Adam M ^a,b   Williams, Dominic P ^a   Ranganath, Lakshminarayan R ^a,c   Gallagher, James A ^a   Jarvis, Jonathan C ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b LANCASTER UNIVERSITY   (United Kingdom)

^c ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME INHIBITOR; HOMOGENTISIC ACID; NITISONE; UNCLASSIFIED DRUG;

ALKAPTONURIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD CHEMISTRY; CARTILAGE CELL; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTOPATHOLOGY; MALE; MOUSE; NONHUMAN; OCHRONOSIS; OSTEOARTHROPATHY; PIGMENTATION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; TREATMENT DURATION;

ARTHRITIS; CHONDROCYTES; KNEE OSTEOARTHRITIS; OSTEOARTHRITIS; TREATMENT;

4-HYDROXYPHENYLPYRUVATE DIOXYGENASE; ANIMALS; CHONDROCYTES; CYCLOHEXANONES; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; FEMALE; HUMANS; JOINT DISEASES; KNEE JOINT; MALE; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; NITROBENZOATES; OCHRONOSIS;

EID: 84889672004     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2012-202878     Document Type: Article

References (27)

1. Garrod AE. The incidence of alkaptonuria: a study in chemical individuality. 1902 [classical article]. Yale J Biol Med 1902;75:221-31.
2. Scriver CR. Garrod's Croonian Lectures (1908) and the charter 'Inborn Errors of Metabolism': albinism, alkaptonuria, cystinuria, and pentosuria at age 100 in 2008. J Inherit Metab Dis 2008;31:580-98.
3. La Du BN, Zannoni VG, Laster L, et al. The nature of the defect in tyrosine metabolism in alcaptonuria. J Biol Chem 1958;230:251-60.
4. Fernández-Cañón JM, Granadino B, Beltrán- Valero de Bernabé D, et al. The molecular basis of alkaptonuria. Nat Genet 1996;14:19-24. (Pubitemid 26301542)
5. Zatkova A. An update on molecular genetics of Alkaptonuria (AKU). J Inherit Metab Dis 2011;34:1127-36.
6. Phornphutkul C, Introne WJ, Perry MB, et al. Natural history of alkaptonuria. New Engl J Med 2002;347:2111-21. (Pubitemid 36015123)
7. Helliwell TR, Gallagher JA, Ranganath L. Alkaptonuria - a review of surgical and autopsy pathology. Histopathology 2008;53:503-12.
8. Groseanu L, Marinescu R, Laptoiun D, et al. A late and difficult diagnosis of ochronosis. J Med Life 2010;3:437-43.
9. Perry MB, Suwannarat P, Furst GP, et al. Musculoskeletal findings and disability in alkaptonuria. J Rheumatol 2006;33:2280-5. (Pubitemid 44749789)
10. Gaines JJ, Pai GM. Cardiovascular ochronosis. Arch Pathol Lab Med 1987;111:991-4. (Pubitemid 17145656)
11. Taylor AM, Wlodarski B, Prior IA, et al. Ultrastructural examination of tissue in a patient with alkaptonuric arthropathy reveals a distinct pattern of binding of ochronotic pigment. Rheumatology 2010;49:1412-14.
12. Taylor AM, Boyde A, Wilson PJ, et al. The role of calcified cartilage and subchondral bone in the initiation and progression of ochronotic arthropathy in alkaptonuria. Arthritis Rheum 2011;63:3887-96.
13. Montagutelli X, Lalouette A, Coudé M, et al. AKU, a mutation of the mouse homologous to human alkaptonuria, maps to chromosome 16. Genomics 1994;19:9-11. (Pubitemid 24034358)
14. Taylor AM, Preston AJ, Paulk NK, et al. Ochronosis in a murine model of alkaptonuria is synonymous to that in the human condition. Osteoarthr Cartilage 2012;20:880-6.
15. Manning K, Al-Dhalimy M, Finegold M, et al. In vivo suppressor mutations correct a murine model of hereditary tyrosinemia type I. Proc Natl Acad Sci USA 1999;96:11928-33. (Pubitemid 29502835)
16. Introne WJ, Perry MB, Troendle J, et al. A 3-year randomized therapeutic trial of nitisinone in alkaptonuria. Mol Genet Metab 2011;103:307-14.
17. Manning K, Fernández-Cañón JM, Montagutelli X, et al. Identification of the mutation in the alkaptonuria mouse model. Hum Mutat 1999;13:171.
18. Bory C, Boulieu R, Chantin C, et al. Diagnosis of alcaptonuria: rapid analysis of homogentisic acid by HPLC. Clin Chim Acta 1990;189:7-12. (Pubitemid 20185583)
19. Tinti L, Taylor AM, Santucci A, et al. Development of an in vitro model to investigate joint ochronosis in alkaptonuria. Rheumatology 2011;50:271-7.
20. Deutsch JC, Santhosh-Kumar CR. Quantitation of homogentisic acid in normal human plasma. J Chromatogr B Biomed Appl 1996;677:147-51. (Pubitemid 26077961)
21. Introne WJ, Phornphutkul C, Bernardini I, et al. Exacerbation of the ochronosis of alkaptonuria due to renal insufficiency and improvement after renal transplantation. Mol Genet Metab 2002;77:136-42. (Pubitemid 35178525)
22. Weinstein JR, Anderson S. The aging kidney: physiological changes. Adv Chronic Kidney Dis 2010;17:302-7.
23. Urbieta-Caceres VH, Syed FA, Lin J, et al. Age-dependent renal cortical microvascular loss in female mice. Am J Physiol Endocrinol Metab 2012;302: E979-986.
24. Chow WY, Taylor AM, Reid DG, et al. Collagen atomic scale molecular disorder in ochronotic cartilage from an alkaptonuria patient, observed by solid state NMR. J Inherit Metab Dis 2011;34:1137-40.
25. Taylor AM, Hsueh MF, Ranganath LR, et al. Analysis of cartilage biomarkers of turnover and aging in the osteoarthropathy of alkaptonuria. Osteoarthr Cartilage 2011;19:S80.
26. Stoop R, van der Kraan PM, Buma P, et al. Type II collagen degradation in spontaneous osteoarthritis in C57Bl/6 and BALB/c mice. Arthritis Rheum 1999;42:2381-9. (Pubitemid 30333419)
27. Suzuki Y, Oda K, Yoshikawa Y, et al. A novel therapeutic trial of homogentisic acidiuria in a murine model of alkaptonuria. J Hum Genet 1999;44:79-84. (Pubitemid 29146928)